TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 500 patients (estimated)
- Sponsors
- Turning Point Therapeutics, Inc.
- Collaborators
- Zai Lab (Shanghai) Co., Ltd.
- Tags
- Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 4 days ago
- SparkCures ID
- 1433
- NCT Identifier
- NCT03093116
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.